Seagen, Inc.

$175.13 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Seagen, Inc.

Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.

Stock Analysis

last close $175.13
1-mo return 22.9%
3-mo return 15.3%
avg daily vol. 2.05M
52-week high 192.79
52-week low 105.43
market cap. $33.2B
forward pe -
annual div. -
roe -21.5%
ltg forecast -
dividend yield -
annual rev. $1.7B
inst own. 93.4%
baraka

Subscribe now for daily local and international financial news

Subscribe